Program Affiliation Cont... CTU
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
HPTN
MTCT-Plus
CTU
COVID
MCAP
UTAP
Global TA
PHIA
QICIP
TRACE
CQUIN
GNCBP
OpCon
OPTIMIZE
Project Location
All
Mozambique
Angola
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Burundi
Liberia
Philippines
Brazil
Guatemala
Georgia
Haiti
China
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kazakhstan
Kyrgyzstan
Kenya
Namibia
Ethiopia
Nigeria
Rwanda
Tajikistan
Malawi
Sierra Leone
Zimbabwe
Tanzania
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
Central Asia
january
HPTN 084 Study: Eswatini Prevention Center
Project Details
A Phase 3 Double-Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Project Details
A Randomized Non-Inferiority Study
Project Details
Soon to Launch A Randomized Non-Inferiority Study to Assess Immunogenicity, Safety, and Acceptability of Two vs. Three Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults
Project Details
Project Details
A Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Pre-Exposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection
Project Details
Project Details
Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
Project Details
february
HPTN 084 Study: Eswatini Prevention Center
Project Details
A Phase 3 Double-Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Project Details
A Randomized Non-Inferiority Study
Project Details
Soon to Launch A Randomized Non-Inferiority Study to Assess Immunogenicity, Safety, and Acceptability of Two vs. Three Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults
Project Details
Project Details
A Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Pre-Exposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection
Project Details
Project Details
Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
Project Details
march
HPTN 084 Study: Eswatini Prevention Center
Project Details
A Phase 3 Double-Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Project Details
A Randomized Non-Inferiority Study
Project Details
Soon to Launch A Randomized Non-Inferiority Study to Assess Immunogenicity, Safety, and Acceptability of Two vs. Three Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults
Project Details
Project Details
A Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Pre-Exposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection
Project Details
Project Details
Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
Project Details
april
HPTN 084 Study: Eswatini Prevention Center
Project Details
A Phase 3 Double-Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Project Details
A Randomized Non-Inferiority Study
Project Details
Soon to Launch A Randomized Non-Inferiority Study to Assess Immunogenicity, Safety, and Acceptability of Two vs. Three Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults
Project Details
Project Details
A Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Pre-Exposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection
Project Details
Project Details
Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
Project Details
may
HPTN 084 Study: Eswatini Prevention Center
Project Details
A Phase 3 Double-Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Project Details
A Randomized Non-Inferiority Study
Project Details
Soon to Launch A Randomized Non-Inferiority Study to Assess Immunogenicity, Safety, and Acceptability of Two vs. Three Doses of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Children, Adolescents and Young Adults
Project Details
Project Details
A Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Pre-Exposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection
Project Details
Project Details
Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern